Franck Laurent Brebion

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Galapagos Nv, Les Laboratoires Servier, Les Laboratories Servier. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Franck Laurent Brebion. Retrieved from https://idiyas.com/inventor/franck-laurent-brebion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 10.6

ph-index = 2

Forward Citations = 7(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

1 out of 53

Les Laboratories Servier

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

2. 10941117 - 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2021-03-09),

3. 10829478 - 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis (2020-11-10),

4. 10550100 - 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis (2020-02-04),

5. 10487060 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2019-11-26),

6. 9926281 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2018-03-27),

Title: Franck Laurent Brebion: Innovator in Pharmaceutical Compounds

Introduction

Franck Laurent Brebion is a notable inventor based in Romainville, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target inflammatory conditions and cartilage degradation. With a total of 6 patents to his name, Brebion's work is recognized for its potential impact on treating osteoarthritis.

Latest Patents

One of Brebion's latest patents involves the development of 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis. This invention discloses compounds according to a specific formula, wherein various components are defined. The invention relates to compounds that inhibit ADAMTS, methods for their production, and pharmaceutical compositions that include these compounds. The methods of treatment aim to prevent or treat inflammatory conditions and diseases that involve the degradation of cartilage and disruption of cartilage homeostasis.

Career Highlights

Throughout his career, Franck Laurent Brebion has worked with prominent companies in the pharmaceutical industry. Notable among these are Galapagos NV and Les Laboratoires Servier. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Brebion has collaborated with several professionals in his field, including Luke Jonathan Alvey and David Amantini. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Franck Laurent Brebion is a distinguished inventor whose work in pharmaceutical compounds has the potential to significantly improve treatments for osteoarthritis and related conditions. His contributions to the field are marked by a commitment to innovation and collaboration.

Profile summary based on public USPTO records.